Bitter tonic Choleretic (increases liver bile production) Immune-stimulating
Andrographis Herbal Benefits
Liver Health || Immune Support || Cold & Flu Cough Relief || Digestion
Andrographis is traditionally used for its immune-boosting properties and is commonly used to help manage the common cold, flu, sore throat, and upper respiratory infections. The active compound in Andrographis that is thought to be responsible for its immune-supportive effects is called andrographolide. This compound has been shown to enhance the activity of immune cells called macrophages, which help to remove cellular debris and promote tissue repair.
Andrographis is a plant that is commonly used to support respiratory health. A study published in 2004 found that andrographis extract may be effective in managing acute respiratory infections and was more effective than a placebo in reducing cold symptoms like nasal congestion, earache, and sore throat. Andrographis is one of the most widely used herbal medicines for respiratory health and is often used as a natural remedy for these types of conditions.
Andrographis paniculata has been shown to promote healthy liver and gallbladder function. It does this by increasing bile flow, supporting the production of a compound called glutathione, and reducing liver damage. Several studies have found that andrographolides, a compound found in andrographis paniculata, may be as effective as St. Mary's Thistle (Silybum marianum) in protecting the liver.
Andrographis Typical Use
Tea & Infusion
5-6 grams steeped in a cup of hot water for 5-10 minutes.
Tincture & Liquid Extract
Typical use of Andrographis tincture is 2.5mls mixed in a small amount of water or juice 1-2 times daily, or as directed by your practitioner.
Caceres DD, Hancke JL, Burgos RA, et al. Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized, double-blind, placebo study. Phytomedicine 1999;6:217-23. https://www.ncbi.nlm.nih.gov/pubmed/10465169
Suebsasana, S, et al.: Analgesic, antipyretic, anti-inflammatory and toxic effects of andrographolide derivatives in experimental animals. Archives of Pharmacal Research. 32(9), 2009, 1191–1200.Tang, T, et al.: Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 33(2), 2011, 194–202. https://pubmed.ncbi.nlm.nih.gov/19784573
Spasov, AA, et al.: Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children. Phytother Res. 18(1), 2004, 47–53. https://pubmed.ncbi.nlm.nih.gov/14750201
Sheeja, K, et al.: Antioxidant and anti-inflammatory activities of the plant Andrographis paniculata Nees. Immunopharmacol Immunotoxicol. 28(1), 2006, 129–140. https://pubmed.ncbi.nlm.nih.gov/16684672
This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal primary healthcare practitioner. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Naturopath Herbals nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their doctors or qualified health professionals before beginning any herbal product, nutritional supplement or lifestyle program.
PharyngotonsillitisA clinical benefit of andrographis in the treatment of pharyngotonsillitis was reported in one early RCT involving 152 volunteers (Thamlikitkul et al 1991). Symptoms of sore throat and fever were reduced at a dose of 6 g/day of a non-standardised andrographis preparation after 3 days. No subsequent research appears to have been conducted for this indication to confirm these results.Ulcerative colitisTwo RCTs have found benefits for andrographis treatment in mild to moderate ulcerative colitis.The efficacy of Andrographis paniculata (HMPL-004) in the treatment of mild to moderate ulcerative colitis was assessed in a double-blind RCT (n = 224) (Sandborn et al 2013). Two different strengths of andrographis (1200 mg, or 1800 mg per day) were compared to placebo over 8 weeks. By the end of the treatment period, a clinical response was achieved in 60% of patients receiving andrographis 1800 mg/day (P = 0.02), compared to 45% taking the 1200 mg dose and 40% of those taking placebo (P = 0.6 andrographis 1200 mg vs placebo) (Sandborn et al 2013). Therefore, only the higher strength was significantly superior to placebo whereas the lower dose of andrographis was not effective. Interestingly, the lower dose of andrographis 1200 mg (HMPL-004) daily was as effective as slow-release mesalazine (4500 mg/day) after 8 weeks in another multicentre RCT involving 120 patients with mild to moderate ulcerative colitis (Tang et al 2011).Rheumatoid arthritisAnti-inflammatory and immunomodulating effects have been observed in laboratory and animal studies providing the basis of investigation into the effects of andrographis in rheumatoid arthritis. To date, only one clinical study has been published, producing promising results.Treatment with andrographis tablets (standardised to 30 mg andrographolide/tablet) three times a day for 14 weeks significantly reduced joint tenderness, number of swollen or tender joints and total grade of swollen or tender joints compared to placebo in a double-blind RCT involving 60 patients with active rheumatoid arthritis (Burgos et al 2009). A reduction in rheumatoid factor IgA and C4 was also observed. Of note, participants were not permitted to take non-steroidal anti-inflammatory drugs during the study and paracetamol was only used in cases of severe pain. Joint pain intensity decreased in the andrographis treatment group compared to the placebo group, but the difference was not statistically significant (Burgos et al 2009).